ABSTRACT Purpose Our objective was to investigate the prevalence of SWA, associated factors, relationship with STIs, and behavioral aspects in men attended at Referral Centers for STIs and acquired immunodeficiency syndrome (AIDS)/CR-STI/AIDS in northeast Brazil. Materials and Methods In this cross-sectional study, a questionnaire with sociodemographic, clinical, sexual and SWA practices information was applied to 400 men attended at two CR-STI/AIDS in Northeast Brazil on the years of 2018 and 2019. Clinical and laboratory diagnoses of STIs were confirmed in medical records. Logistic regression models were performed to identify the independent predictors for SWA. Results The prevalence of SWA over total samples was 15.00%. Of the participants, 239 (59.75%) of the participants were diagnosed with STIs, and of these 37 (15.48%) reported SWA. Most men practiced SWA in adolescence, being the last episode more than 20 years ago, usually with asinine and mules, in vaginal route and without a condom. SWA practitioners have higher percentages of occurrence of some viral STIs. SWA was associated with increasing age, history of residence in a rural area with remained over 12 years, married or widowed/separated, heterosexuals, with less than 7 years of study, Catholics, with hepatitis B, former user of alcoholic beverages and smokers, with a history of STI and intercourse with sex workers. Conclusion SWA practices increase STIs vulnerability. The association between hepatitis B and SWA highlights the importance of educational campaigns and conclusive studies on the topic. factors AIDS/CRSTI/AIDS AIDSCRSTIAIDS AIDS /CR STI/AIDS CR crosssectional cross sectional study sociodemographic clinical 40 CRSTI/AIDS CRSTIAIDS 201 2019 records 1500 15 00 15.00% 23 59.75% 5975 59 75 (59.75% 3 15.48% 1548 48 (15.48% adolescence 2 ago mules condom age 1 widowedseparated widowed separated widowed/separated heterosexuals Catholics smokers workers vulnerability topic CRSTI STIAIDS 4 150 0 15.00 59.75 597 5 (59.75 15.48 154 (15.48 15.0 59.7 (59.7 15.4 (15.4 15. 59. (59. (15. (59 (15 (5 (1 (

RESUMO RACIONAL: O câncer colorretal (CCR) é um problema de saúde mundial cujo controle depende do estabelecimento de políticas públicas e programas de prevenção e rastreamento eficazes. No Brasil existem poucos estudos relacionados à adesão métodos de rastreamento. OBJETIVO: Avaliar a associação de características sócio-demográficas à realização de testes de sangue oculto nas fezes do tipo imunoquimicomecanizado (FIM) em população de médio risco para o desenvolvimento de câncer colorretal. MÉTODOS: Estudo observacional transversal, com coleta prospectiva de dados. Entre março de 2015 e abril de 2016, 1.254 indivíduos assintomáticos, com idade entre 50 e 75 anos, foram consecutivamente selecionados a partir de uma campanha hospitalar de rastreamento para neoplasias. RESULTADOS: As taxas de adesão ao teste FIM foi 55.6% (697/1254). Na análise de regressão logística múltipla os fatores independentes associados à adesão ao rastreamento do CCR foram: Idade entre 60–75 anos (oddsratio (OR)=1.30; intervalo de confiança de 95% (IC): 1.02–1.66; p=0.03), crença religiosa (OR=2.04; 95%IC: 1.34–3.11; p<0.01), realização prévia de exame de sangue oculto nas fezes (OR=2.07; 95%IC: 1.55–2.76; p<0.01) e vínculo empregatício em período integral ou parcial (OR=0.66; 95%IC: 0.49–0.89; p<0.01). CONCLUSÃO: Este estudo enfatiza a importância de considerar aspectos laborais ao implementar programas de rastreamento do câncer colorretal e sugere que campanhas de rastreamento implantadas no ambiente de trabalho e de maneira repetida ao longo dos anos podem ser mais efetivas. RACIONAL (CCR eficazes OBJETIVO sóciodemográficas sócio demográficas (FIM MÉTODOS transversal dados 201 2016 1254 1 254 1.25 assintomáticos 5 7 neoplasias RESULTADOS 556 55 6 55.6 697/1254. 6971254 697/1254 . 697 (697/1254) 6075 60 60–7 oddsratio OR=1.30 OR130 OR =1.30 30 (OR)=1.30 95 IC (IC) 1.02–1.66 102166 02 66 p=0.03, p003 p p=0.03 , 0 03 p=0.03) OR=2.04 OR204 2 04 (OR=2.04 95%IC 95IC 1.34–3.11 134311 34 3 11 p<0.01, p001 p<0.01 01 OR=2.07 OR207 07 (OR=2.07 1.55–2.76 155276 76 OR=0.66 OR066 (OR=0.66 0.49–0.89 049089 49 89 p<0.01. CONCLUSÃO efetivas 20 125 25 1.2 55. 697125 697/125 69 (697/1254 607 60– OR=1.3 OR13 130 =1.3 (OR)=1.3 9 (IC 1.02–1.6 10216 p00 p=0.0 OR=2.0 OR20 (OR=2.0 1.34–3.1 13431 p<0.0 1.55–2.7 15527 OR=0.6 OR06 (OR=0.6 0.49–0.8 04908 4 8 12 1. 69712 697/12 (697/125 OR=1. OR1 13 =1. (OR)=1. 1.02–1. 1021 p0 p=0. OR=2. OR2 (OR=2. 1.34–3. 1343 p<0. 1.55–2. 1552 OR=0. OR0 (OR=0. 0.49–0. 0490 6971 697/1 (697/12 OR=1 =1 (OR)=1 1.02–1 102 p=0 OR=2 (OR=2 1.34–3 134 p<0 1.55–2 155 OR=0 (OR=0 0.49–0 049 697/ (697/1 OR= = (OR)= 1.02– 10 p= (OR= 1.34– p< 1.55– 15 0.49– (697/ (OR) 1.02 (OR 1.34 1.55 0.49 (697 1.0 1.3 1.5 0.4 (69 0. (6 (

ABSTRACT BACKGROUND Colorectal cancer (CRC) is a worldwide health problem whose control depends on public policy establishment and effective prevention and screening programs. In Brazil, there are few studies related to adherence to screening methods. AIMS: The aim of this study was to evaluate the association between demographic and socioeconomic to adherence to CRC screening with fecal immunochemical test (FIT) among average-risk individuals for CRC. METHODS: In this prospective cross-sectional study, conducted between March 2015 and April 2016, 1,254 asymptomatic individuals aged 50–75 years, participating in a hospital screening campaign in Brazil, were invited to participate in the study. RESULTS: The adherence rate to FIT was 55.6% (697/1,254). In the multivariable logistic regression analysis, patients aged 60–75 years (odds ratio (OR)=1.30; 95% confidence interval (CI): 1.02–1.66; p=0.03), religious belief (OR=2.04; 95% CI: 1.34–3.11; p<0.01), previous fecal occult blood test (OR=2.07; 95% CI: 1.55–2.76; p<0.01), and full/part-time working status (OR=0.66; 95% CI: 0.49–0.89; p<0.01) were independently associated with adherence to CRC screening. CONCLUSION: The results of the present study highlight the importance of considering the labor aspects when implementing screening programs, suggesting that campaigns conducted in the workplace and repeated over the years may be more effective. (CRC programs Brazil methods AIMS (FIT averagerisk average risk METHODS crosssectional cross sectional 201 2016 1254 1 254 1,25 5075 50 75 50–7 RESULTS 556 55 6 55.6 697/1,254. 6971254 697/1,254 . 697 (697/1,254) analysis 6075 60 60–7 odds OR=1.30 OR130 OR =1.30 30 (OR)=1.30 95 CI (CI) 1.02–1.66 102166 02 66 p=0.03, p003 p p=0.03 , 0 03 p=0.03) OR=2.04 OR204 2 04 (OR=2.04 1.34–3.11 134311 34 3 11 p<0.01, p001 p<0.01 01 OR=2.07 OR207 07 (OR=2.07 1.55–2.76 155276 76 full/parttime fullparttime full/part time full part OR=0.66 OR066 (OR=0.66 0.49–0.89 049089 49 89 CONCLUSION 20 125 25 1,2 507 5 7 50– 55. 697125 697/1,25 69 (697/1,254 607 60– OR=1.3 OR13 130 =1.3 (OR)=1.3 9 (CI 1.02–1.6 10216 p00 p=0.0 OR=2.0 OR20 (OR=2.0 1.34–3.1 13431 p<0.0 1.55–2.7 15527 parttime fullpart OR=0.6 OR06 (OR=0.6 0.49–0.8 04908 4 8 12 1, 69712 697/1,2 (697/1,25 OR=1. OR1 13 =1. (OR)=1. 1.02–1. 1021 p0 p=0. OR=2. OR2 (OR=2. 1.34–3. 1343 p<0. 1.55–2. 1552 OR=0. OR0 (OR=0. 0.49–0. 0490 6971 697/1, (697/1,2 OR=1 =1 (OR)=1 1.02–1 102 p=0 OR=2 (OR=2 1.34–3 134 p<0 1.55–2 155 OR=0 (OR=0 0.49–0 049 697/1 (697/1, OR= = (OR)= 1.02– 10 p= (OR= 1.34– p< 1.55– 15 0.49– 697/ (697/1 (OR) 1.02 (OR 1.34 1.55 0.49 (697/ 1.0 1.3 1.5 0.4 (697 1. 0. (69 (6 (

OBJECTIVES: Breast cancer (BC) is the most common neoplasm in women. Biopsy of metastatic lesions is recommended to confirm estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status as there are discrepancies in these patterns between primary tumors and metastases in up to 40% of the cases. Circulating tumor cells (CTCs) are related to BC outcomes and could potentially be an alternative to the invasive procedures of metastasis rebiopsy. ISET® technology is not currently employed to detect CTCs in patients with BC. Emerging data support that the characterization of CTC protein expression can refine its prognostic value. Transforming growth factor (TGF)-β plays a role in BC progression and invasiveness. Thus, in this study, we aimed to compare ER, PR, and HER2 expression in primary tumors, CTCs, and metastases and evaluate TGF-β type 1 receptor (TGF-β RI) expression in CTCs as prognostic factor for progression free survival (PFS) and overall survival (OS). METHODS: This prospective study was conducted at the A.C. Camargo Cancer Center, Brazil. Blood samples were processed in ISET® (Isolation by SizE of Tumors, Rarecells, France) before computed tomography-guided biopsy of suspected metastatic lesions. Protein expression levels in CTCs were compared to those in primary tumors/metastases (medical records). RESULTS: Of the 39 patients initially included, 27 underwent both biopsies of metastases and blood collection and were considered for analysis. The concordance rates for ER, PR, and HER2 expression between primary tumors and metastases were high. No loss of HER2 expression at any metastasis site and retention of the same pattern of protein expression in all triple-negative (TN) tumors (92.5%, 81.5% and 96.2% respectively) (p<0.0001) was observed. When metastases/CTCs were classified as TN/non-TN, CTCs showed high specificity (93%), accuracy (84.2%), and negative predictive value (88%). The median OS of patients without TGF-β RI expression in CTCs was 42.6 versus 20.8 months for TGF-β RI expression-positive ones (p>0.05). CONCLUSION: The role of CTCs detected by ISET has not yet been established in BC. Here, we suggest that this methodology may be useful to evaluate metastasis in non-TN cases as well as TGF-β RI expression in CTCs, which may impact patient survival. Due to sample limitations, future studies must focus on specific BC subtypes and an expansion of the cohort.

Abstract Background: The mitotic index is no longer used to classify T1 melanoma patients into T1a and T1b, so it should not be used to indicate sentinel node biopsy in these patients. Objectives: To evaluate patients with T1 melanoma who underwent sentinel lymph node biopsy and to compare those who were classified as T1a with those classified T1b, according to the 7th and 8th Edition of the melanoma staging system, regarding a positive biopsy result. The authors also aimed to assess whether there is any difference in the results in both staging systems. Material and methods: This was a retrospective analysis of 1213 patients who underwent sentinel lymph node biopsy for melanoma, from 2000 to 2015, in a single institution. Results: Of 399 patients with thin melanomas, 27 (6.7%) presented positive sentinel lymph nodes; there was no difference in positivity for sentinel node biopsy when comparing T1a vs. T1b in both staging systems. Furthermore, the clinical results were also similar between the two groups. However, in the complete cohort analysis, the mitotic index was associated with positivity for sentinel lymph node biopsy (p < 0.0001), positivity for non-sentinel lymph node (p < 0.0001), recurrence-free survival (p < 0.0001), and specific melanoma survival (p = 0.023). Study limitation: Unicentric study. Conclusion: The mitotic index was shown to be a very important prognostic factor in the present study, but it was not observed in patients classified as T1. The mitotic index should no longer be used as the only reason to refer sentinel lymph node biopsy in patients with thin melanoma.

RESUMO CONTEXTO: Estudos hospitalares recentes têm demonstrado aumento da sobrevida do câncer colorretal e melhor sobrevida para mulheres, jovens e pacientes diagnosticados em estágio precoce da doença. OBJETIVO: Descrever a sobrevida global e analisar os fatores prognósticos de pacientes tratados para câncer colorretal em um centro de oncologia. MÉTODOS: Foram incluídos pacientes com diagnóstico de adenocarcinoma de cólon e reto entre 2000 e 2013, identificados no Registro Hospitalar de Câncer do A.C.Camargo Cancer Center. A sobrevida global aos 5 anos foi estimada pelo método de Kaplan-Meier e os fatores prognósticos foram avaliados pelo modelo de Cox. As razões de risco (HR) são relatadas com intervalos de confiança (IC) de 95%. RESULTADOS: Dos 2.279 casos de câncer colorretal analisados, 58,4% eram de cólon. A taxa de sobrevida global aos 5 anos para pacientes com câncer colorretal foi de 63,5% (65,6% e 60,6% para câncer de cólon e retal, respectivamente). O risco de óbito foi elevado para pacientes na faixa etária de 50-74 anos (HR=1,24; IC95% =1,02-1,51) e ≥75 anos (HR=3,02; IC95% =2,42-3,78), para pacientes com câncer retal (HR=1,37; IC95% =1,11-1,69) e para aqueles cujo tratamento foi iniciado >60 dias após o diagnóstico (HR=1,22; IC95% =1,04-1,43). O risco diminuiu para pacientes diagnosticados em períodos recentes (2005-2009 HR=0,76; IC95% =0,63-0,91; 2010-2013 HR=0,69; IC95% =0,57-0,83). CONCLUSÃO: A sobrevida dos pacientes com câncer colorretal é maior naqueles em estágio inicial e com início do tratamento antes dos 60 dias.. Idade acima de 70 anos foi fator independente preditivo de mau prognóstico. A sobrevida global aumentou para todos os pacientes tratados no período de 2000-2004 a 2010-2013.

ABSTRACT BACKGROUND: Hospital-based studies recently have shown increases in colorectal cancer survival, and better survival for women, young people, and patients diagnosed at an early disease stage. OBJECTIVE: To describe the overall survival and analyze the prognostic factors of patients treated for colorectal cancer at an oncology center. METHODS: The analysis included patients diagnosed with colon and rectal adenocarcinoma between 2000 and 2013 and identified in the Hospital Cancer Registry at A.C.Camargo Cancer Center. Overall 5-year survival was estimated using the Kaplan-Meier method, and prognostic factors were evaluated in a Cox regression model. Hazard ratios (HR) are reported with 95% confidence intervals (CI). RESULTS: Of 2,279 colorectal cancer cases analyzed, 58.4% were in the colon. The 5-year overall survival rate for colorectal cancer patients was 63.5% (65.6% and 60.6% for colonic and rectal malignancies, respectively). The risk of death was elevated for patients in the 50-74-year (HR=1.24, 95%CI =1.02-1.51) and ≥75-year (HR=3.02, 95%CI =2.42-3.78) age groups, for patients with rectal cancer (HR=1.37, 95%CI =1.11-1.69) and for those whose treatment was started >60 days after diagnosis (HR=1.22, 95%CI =1.04-1.43). The risk decreased for patients diagnosed in recent time periods (2005-2009 HR=0.76, 95%CI =0.63-0.91; 2010-2013 HR=0.69, 95%CI =0.57-0.83). CONCLUSION: Better survival of patients with colorectal cancer improves with early stage and started treatment within 60 days of diagnosis. Age over 70 years old was an independent factor predictive of a poor prognosis. The overall survival increased to all patients treated in the period 2000-2004 to 2010-2013.